Monitoring vital signs during infusion with infliximab does neither indicate nor predict development of acute infusion reactions.
de Vries
Hilbert S
HS
van Oijen
Martijn G H
MG
van Hoven-van Loo
Karin E J
KE
de Jong
Dirk J
DJ
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001794:Blood Pressure; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D007262:Infusions, Intravenous; D011237:Predictive Value of Tests; D011674:Pulse; D013696:Temperature; D014409:Tumor Necrosis Factor-alpha
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab